OakChart

InspireMD Inc

NSPRHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.8000+0.0200 (2.56%)
2026-11-11 22:37 CET
Market cap
36.26 USD m
Revenue, TTM
10.84 USD m
Net income, TTM
-52.48 USD m
Free cash flow, TTM
-42.46 USD m
EPS diluted, TTM
-0.65
P/E
-
Compare

Price

NSPR against its 20, 50 and 200-day averages
2050200beatearnings
0.501.001.502.00425K851KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NSPRclose 0.8020-day 0.5550-day 0.63200-day 1.030.8052w low

64.0% under the 52-week high of 2.22 on 17 Nov 2025. 52-week low 0.43 on 21 Oct 2026. Last 15 sessions, 90.3% high to low

Volume 1.39× normal · the line is the 50-bar volume average

Profile

NSPR
52-week range, 21% of the way up
0.432.22

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Employees127
IPOApr 11, 2011
Beta0.80
ATR, 14d0.09
Rel volume1.39
Short float0.76%
Insider own28.87%
Inst own40.49%

Snapshot

6 groups

Valuation

Index-
Market Cap37.19M
Enterprise Value9.79M
Income-52.48M
Sales10.84M
Book/sh0.67
Cash/sh0.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees127
IPOApr 11, 2011

Ratios

P/E-
Forward P/E-
PEG-
P/S3.43
P/B1.19
P/C1.22
P/FCF-
EV/EBITDA-
EV/Sales0.90
Quick Ratio3.52
Current Ratio3.80
Debt/Eq0.10
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.65
EPS next Y-0.48
EPS next Q-0.15
EPS this Y19.30%
EPS next Y21.20%
EPS next 5Y-
EPS past 3/5Y31.40% 35.83%
Sales past 3/5Y20.19% 29.29%
EPS Y/Y TTM22.08%
Sales Y/Y TTM53.42%
EPS Q/Q34.37%
Sales Q/Q-0.39%
EarningsNov 12 BMO
EPS/Sales Surpr.15.00% 28.05%

Ownership

Insider Own28.87%
Insider Trans0.35%
Inst Own40.49%
Inst Trans-4.52%
ROA-134.60%
ROE-202.81%
ROIC-156.76%
Gross Margin18.05%
Oper. Margin-494.03%
Profit Margin-484.11%
SMA2044.83%
SMA5026.26%
SMA200-22.56%
Trades-

Technical

Shs Outstand46.92M
Shs Float33.07M
Short Float0.76%
Short Ratio1.41
Short Interest0.25M
52W High2.22 -63.96%
52W Low0.43 88.06%
Volatility22.14% 15.59%
ATR (14)0.09
RSI (14)67.53
Beta0.80
Rel Volume1.39
Avg Volume178.22K
Volume247,305

Performance

Perf Week2.43%
Perf Month60.00%
Perf Quarter-4.77%
Perf Half Y-31.62%
Perf YTD-55.06%
Perf Year-50.92%
Perf 3Y-74.52%
Perf 5Y-80.77%
Perf 10Y-100.00%
Recom1.00
Target Price3.33
Prev Close0.78
Price0.80
Change %2.56%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Feb 02, 2026InitiatedMMaxim GroupBuy$6+650.0%
Jan 07, 2016InitiatedRRodman & RenshawBuy$4+400.0%
Mar 13, 2015DowngradeOOppenheimerOutperform → Perform
Nov 26, 2013InitiatedOOppenheimerOutperform$6+650.0%

Peers

Mkt cap
TickerCompanyMkt cap
PENPenumbra Inc12.68B
AORTArtivion Inc980.68M
CVRXCVRx Inc19.95M
AVRAnteris Technologies Global Corp604.46M
LMATLemaitre Vascular Inc1.81B
NVNOenVVeno Medical Corp4.53M
ELUTElutia Inc40.75M
ANGOAngiodynamic Inc522.32M
ADGMAdagio Medical Holdings Inc1.71M
TMDXTransmedics Group Inc3.20B

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Stuka PaulDirectorMay 27 '26Buy0.8820,00017,500667,871May 29 04:05 PM
Gleason Shane ThomasChief Commercial OfficerMay 19 '26Sale1.0122,77823,0061,053,882May 21 05:16 PM
Gleason Shane ThomasChief Commercial OfficerFeb 02 '26Sale1.592,9414,6761,076,660May 21 05:16 PM
Stuka PaulDirectorMay 13 '26Buy1.1610,00011,575642,871May 15 04:05 PM
Stuka PaulDirectorMay 14 '26Buy1.155,0005,750647,871May 15 04:05 PM
Slosman MarvinCEO and PresidentMay 12 '26Buy1.2021,00025,2003,556,658May 13 05:00 PM
Stuka PaulDirectorMay 08 '26Buy1.1665,62676,126622,871May 12 07:35 PM
Stuka PaulDirectorMay 11 '26Buy1.1910,00011,900632,871May 12 07:35 PM
Ward Scott R.DirectorMay 07 '26Buy1.1573,25584,243237,096May 08 05:08 PM
Ward Scott R.DirectorMay 06 '26Buy1.1515,99518,394163,841May 08 05:08 PM
Stuka PaulDirectorMay 07 '26Buy1.156,3787,335531,599May 08 05:05 PM
Stuka PaulDirectorMay 06 '26Buy1.121,5171,699525,221May 08 05:05 PM
ROUBIN GARY SDirectorMay 07 '26Buy1.1890,000106,200834,478May 08 05:03 PM
Gleason Shane ThomasChief Commercial OfficerJan 21 '26Sale1.6217,59328,5531,174,664Feb 02 05:01 PM

Held by

AUM
TickerCompanyAUM
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 100
  • InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results (GlobeNewswire)
  • InspireMD Needs Proof Its Revenue Slide Has Bottomed As Shares Trade Near $0.66 (Earnings Whispers) +18.71% -18.18%
  • InspireMD to Announce Third Quarter 2026 Financial Results (GlobeNewswire)
  • InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million (GlobeNewswire)
  • InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ... (GuruFocus.com) -10.44%
  • InspireMD Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • InspireMD to Announce Second Quarter 2026 Financial Results (GlobeNewswire) +8.03% +6.54%
  • InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing (GlobeNewswire)
  • InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures (GlobeNewswire) -5.95%
  • InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures (GlobeNewswire) -7.24%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.153--2.003
2026Q22026-08-17-0.170-0.200-0.1701.771.383
2026Q12026-05-04-0.160-0.180-0.1633.402.703
2025Q42026-03-18-0.140-0.193-0.1433.152.633
2025Q32025-11-04-0.170-0.195-0.1732.521.762
2025Q22025-08-05-0.260-0.260-0.2581.781.522
2025Q12025-05-09-0.220-0.200-0.2231.531.452
2024Q42025-03-12-0.190-0.195-0.1881.951.822
2024Q32024-11-12-0.160-0.200-0.1631.811.741
2024Q22024-08-06-0.220-0.190-0.2201.741.741
2024Q12024-05-14-0.210--0.2051.51--
2023Q42024-03-06-0.160-0.195-0.2481.761.632
2023Q32023-11-06-0.150-0.140-0.1521.561.501
2023Q22023-08-08-0.240-0.430-0.2411.651.551
2023Q12023-05-16-0.530-0.680-0.5261.241.001
2022Q42023-03-30-0.600-0.840-0.6031.031.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY-1,463,437-1,529,062-36,651,5632.312.59
2017FY-26,235--16,9912.76-
2018FY-247.5--250.123.60-
2019FY-72.000-84.450-72.0593.724.30
2020FY-6.900-6.000-6.9722.493.50
2021FY-2.030-2.300-2.0314.504.50
2022FY-2.350-2.590-2.3495.175.00
2023FY-0.820-0.870-0.8216.216.10
2024FY-0.770-0.780-0.7637.016.90
2025FY-0.760-0.833-0.7608.988.45
2026FY--0.613--9.80
2027FY--0.483--20.13

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-313002.001.882.11
2026Q3S2026-08-173122.001.882.11
2026Q3S2026-07-193002.131.802.60
2026Q3S2026-07-153022.131.802.60
2026Q3S2026-05-053032.131.802.60
2026Q3S2026-05-013023.141.803.81
2026Q3S2026-03-183023.643.303.81
2026Q3S2026-01-303003.973.814.21
2026Q3S2025-11-112004.053.904.21
2026Q3S2025-11-102004.053.904.21
2026Q3S2025-11-092004.053.904.21
2026Q3S2025-11-082004.053.904.21
2026Q3S2025-11-072004.053.904.21
2026Q3S2025-11-062004.053.904.21

Estimate history

EPS, annual-16990.838-250.118-72.059-6.972-2.031-2.349-0.821-0.763-0.758-0.6483
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.22-0.163-0.188-0.223-0.258-0.173-0.143-0.163-0.169
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.7613.6013.7212.4854.4955.1716.2057.0098.97910.84
Period201720182019202020212022202320242025TTM
Sales, quarterly1.7391.811.9491.5291.7782.5233.1493.3981.771
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0020.0510.2613.2848.2968.33121.84126.61143.53246.921
Period201720182019202020212022202320242025MRQ
Shares, quarterly25.19625.7226.61129.75332.55341.91943.53246.83946.921
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue10.848.987.016.215.174.502.483.723.60
Cost of Goods Sold Incl. D&A8.886.335.504.404.053.742.402.962.61
Gross Profit1.962.651.511.811.120.750.080.760.99
Selling, General and Administrative Excl. Other55.5251.7634.7222.6919.5915.2110.1910.028.61
Research and Development16.1715.0013.637.987.815.162.232.601.53
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-53.56-49.11-33.21-20.89-18.47-14.45-10.10-9.27-7.61
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.500.290.260.240.270.280.55-0.44
Net Income Before Taxes-52.42-48.72-31.95-19.85-18.46-14.87-10.54-10.02-7.24
Income Taxes0.060.060.060.070.030.040.000.020.00
Consolidated Net Income-52.48-48.79-32.01-19.92-18.49-14.92-10.54-10.04-7.24
Net Income From Continuing Operations-52.48-48.79-32.01-19.92-18.49-14.92-10.54-10.04-7.24
Net Income-52.48-48.79-32.01-19.92-18.49-14.92-10.54-10.04-7.70
EPS (Recurring)-0.62-0.75-0.76-0.81-2.33-2.01-6.84-69.29-260.08
EPS (Basic, Before Extraordinaries)-0.65-0.76-0.76-0.82-2.35-2.03-6.97-72.06-250.12
EPS (Diluted)-0.65-0.76-0.76-0.82-2.35-2.03-6.97-72.06-250.12
EBITDA-52.98-48.64-32.93-20.66-18.28-14.29-9.95-9.11-7.46
Non-Operating Income (Expense)1.140.891.561.290.25-0.16-0.16-0.20-0.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.609.748.013.551.861.150.440.240.07
Price To Sales Ratio5.4712.7515.7310.991.314.943.110.611.02
Gross Margin18.0529.5021.4929.1221.6016.773.3420.3227.63
Operating Margin-494.03-546.97-473.82-336.62-357.22-321.49-406.60-248.99-211.36
Net Margin-484.11-543.33-456.63-320.97-357.59-331.88-424.31-269.82-213.72
Shares Outstanding46.9243.5326.6121.848.338.303.280.260.05
Market Capitalization36.2636.2668.6060.557.1624.3916.794.236.10

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.773.403.152.521.781.531.951.81
Cost of Goods Sold Incl. D&A2.542.711.971.661.471.241.481.40
Gross Profit-0.770.691.180.860.310.290.470.41
Selling, General and Administrative Excl. Other13.6714.6613.2613.9113.3311.759.848.88
Research and Development4.294.763.483.633.834.063.693.92
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.45-13.98-12.08-13.05-13.02-11.46-9.37-8.46
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-14.32-13.69-11.70-12.71-13.15-11.17-9.12-7.89
Income Taxes0.000.000.060.000.000.000.060.00
Consolidated Net Income-14.32-13.69-11.76-12.71-13.15-11.17-9.17-7.89
Net Income From Continuing Operations-14.32-13.69-11.76-12.71-13.15-11.17-9.17-7.89
Net Income-14.32-13.69-11.76-12.71-13.15-11.17-9.17-7.89
EPS (Recurring)-0.17-0.16-0.14-0.17-0.26-0.22-0.19-0.16
EPS (Basic, Before Extraordinaries)-0.17-0.16-0.14-0.17-0.26-0.22-0.19-0.16
EPS (Diluted)-0.17-0.16-0.14-0.17-0.26-0.22-0.19-0.16
EBITDA-14.29-13.83-11.94-12.92-12.91-11.36-9.29-8.39
Non-Operating Income (Expense)0.120.290.390.34-0.130.290.250.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.702.102.253.543.212.730.222.44
Price To Sales Ratio5.4712.5916.3322.7616.3919.1418.3419.00
Gross Margin-43.7020.2237.4734.2417.6019.1024.0622.87
Operating Margin-815.64-411.36-383.74-517.28-732.23-749.51-480.61-467.51
Net Margin-808.81-402.85-373.48-503.69-739.65-730.28-470.70-435.91
Shares Outstanding46.9246.8443.5341.9232.5529.7526.6125.72
Market Capitalization36.2676.2975.42100.5569.5479.8768.6068.89

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments54.2134.6439.0217.8034.0412.645.519.383.71
Short Term Receivables2.572.252.451.251.390.940.970.820.85
Inventories3.402.572.111.621.141.421.241.130.53
Other Current Assets1.301.060.580.660.520.330.090.080.06
Total Current Assets61.4740.5244.1621.3337.0915.347.8111.425.16
Net Property, Plant & Equipment6.344.732.532.471.711.711.480.420.48
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets1.591.550.950.860.910.720.590.450.48
Total Assets69.4046.8147.6424.6539.7117.789.8812.296.11
Short Term Debt Incl. Current Port. of LT Debt1.070.540.560.420.420.400.360.000.00
Accounts Payable1.251.250.940.660.890.240.650.930.33
Other Current Liabilities8.395.884.523.993.033.072.111.992.15
Total Current Liabilities10.717.686.025.074.353.713.122.922.48
Long Term Debt2.221.801.041.200.781.000.650.000.00
Provision for Risks Charges1.271.251.080.991.050.910.730.600.62
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities14.2010.728.147.266.185.614.503.523.11
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.27
Common Equity55.2036.0939.5017.3933.5312.165.388.762.73
Total Shareholders Equity55.2036.0939.5017.3933.5312.165.388.763.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity55.2036.0939.5017.3933.5312.165.388.763.00
Total Liabilities & Stockholders Equity69.4046.8147.6424.6539.7117.789.8812.296.11
Book Value Per Share1.271.361.812.094.043.7020.62171.111,378.36
Tangible Book Value Per Share1.271.361.812.094.043.7020.62171.111,378.36
Full-Time Employees1278666565248484336
Price to Book Ratio1.161.641.390.330.751.380.790.700.25
Return on Assets-83.96-67.77-55.10-57.46-37.57-76.25-90.58-78.72-108.76
Return on Equity-106.88-84.68-70.01-72.62-44.49-120.19-141.95-123.09-239.51
Return on Invested Capital-84.96-84.49-49.13-99.48-43.48-80.11-166.34-82.62-281.17
Quick Ratio5.424.946.993.898.273.762.113.521.86
Current Ratio5.745.287.344.218.534.142.513.912.08

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-52.48-48.79-32.01-19.92-18.49-14.92-10.54-10.04-7.24
Depreciation0.580.480.280.230.190.160.150.160.15
Other Funds (Non Cash)10.3512.109.124.112.371.610.830.50-0.34
Funds from Operations-41.56-36.21-22.60-15.57-15.94-13.15-9.56-9.38-7.42
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.351.110.74-0.800.40-0.060.48-0.43-0.18
Cash from Operating Activities-41.21-35.10-21.87-16.38-15.54-13.21-9.08-9.81-7.61
Capital Expenditures-1.25-1.66-1.40-0.38-0.47-0.34-0.09-0.28-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.010.010.000.010.000.000.020.00-
Purchase or Sale of Investments-7.20-29.1914.56-15.649.00-22.000.000.000.00
Purchase of Investments-45.09-56.84-14.44-40.14-19.00-24.000.000.000.00
Sale Or Maturity of Investments37.8927.6529.0024.5028.002.000.000.000.00
Other Uses-0.08-0.09-0.51-0.08-0.09-0.11-0.12-0.100.00
Other Sources0.370.370.000.000.000.000.000.000.02
Cash from Investing Activities-8.15-30.5612.64-16.098.44-22.46-0.19-0.39-0.04
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock52.9355.5718.4537.53-0.1435.0316.396.3313.37
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-3.01
Sale of Common Pref Stock52.9355.5718.4537.53-0.1435.0316.396.3316.38
Proceedsfrom Stock Options38.0238.711.600.00-0.140.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities52.9355.5718.4537.53-0.1435.0316.396.3313.37
Exchange Rate Effect0.080.120.05-0.06-0.13-0.010.00-0.01-0.05
Net Change in Cash3.64-9.989.285.01-7.37-0.647.13-3.875.67
Free Cash Flow-42.46-36.77-23.27-16.76-16.02-13.55-9.17-10.09-7.67
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments30.4241.5754.2163.4019.3726.09
Short Term Receivables2.412.792.572.442.092.34
Inventories2.703.043.403.613.052.82
Other Current Assets1.101.201.300.940.950.89
Total Current Assets36.6348.5961.4770.3925.4632.14
Net Property, Plant & Equipment6.296.256.346.326.174.96
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets1.731.631.591.761.711.57
Total Assets44.6456.4769.4078.4733.3438.67
Short Term Debt Incl. Current Port. of LT Debt1.061.071.071.010.920.68
Accounts Payable1.651.951.251.751.521.73
Other Current Liabilities6.946.428.398.066.634.96
Total Current Liabilities9.659.4410.7110.829.077.37
Long Term Debt1.972.042.222.372.511.64
Provision for Risks Charges1.511.371.271.181.521.32
Other Liabilities0.000.000.000.000.000.00
Total Liabilities13.1312.8514.2014.3613.1010.33
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity31.5143.6255.2064.1120.2428.34
Total Shareholders Equity31.5143.6255.2064.1120.2428.34
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity31.5143.6255.2064.1120.2428.34
Total Liabilities & Stockholders Equity44.6456.4769.4078.4733.3438.67
Book Value Per Share0.670.931.271.530.620.95
Tangible Book Value Per Share0.670.931.271.530.620.95
Full-Time Employees--127---
Price to Book Ratio1.161.291.163.882.381.98
Return on Assets-134.60-107.86-83.96-71.65-92.99-89.56
Return on Equity-202.81-142.60-106.88-87.61-123.51-113.95
Return on Invested Capital-42.78-29.98-20.48-19.12-57.81-37.24
Quick Ratio3.524.825.426.172.473.98
Current Ratio3.805.155.746.512.814.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-14.32-13.69-11.76-12.71-13.15-11.17
Depreciation0.160.150.140.130.110.10
Other Funds (Non Cash)2.272.262.193.623.472.82
Funds from Operations-11.89-11.28-9.43-8.96-9.57-8.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.00-1.050.080.331.24-0.54
Cash from Operating Activities-10.89-12.34-9.35-8.63-8.33-8.79
Capital Expenditures-0.33-0.19-0.40-0.33-0.58-0.36
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.000.00
Purchase or Sale of Investments15.0015.00-45.097.895.922.09
Purchase of Investments0.000.00-45.090.00-4.84-6.91
Sale Or Maturity of Investments15.0015.000.007.8910.769.00
Other Uses-0.02-0.03-0.02-0.02-0.02-0.03
Other Sources0.000.000.370.000.000.00
Cash from Investing Activities14.6514.78-45.137.555.321.70
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.0052.932.140.51
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.0052.932.140.51
Proceedsfrom Stock Options0.000.0038.71-0.700.700.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.0052.932.140.51
Exchange Rate Effect0.03-0.020.020.050.000.05
Net Change in Cash3.792.42-54.4651.89-0.87-6.53
Free Cash Flow-11.22-12.53-9.74-8.96-8.91-9.15

Revenue breakdown

Total Surgical & Medical Instruments & Apparatus revenue2024: 7.01M 2025: 8.98M
Germany2024: 926.00K 2025: 1.23M
Italy2024: 1.22M 2025: 1.23M
Other countries2024: 3.42M 2025: 4.06M
Poland2024: 694.00K 2025: 1.04M
Russia2024: 713.00K
United States2024: 32.00K 2025: 1.42M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.76%0.3M33.1M137.27K
2026-10-150.24%0.1M33.1M85.37K
2026-09-300.07%0.0M33.1M74.33K
2026-09-150.08%0.0M33.1M77.30K
2026-08-310.12%0.0M33.2M101.96K
2026-08-140.26%0.1M33.2M115.68K
2026-07-310.26%0.1M33.4M312.53K
2026-07-150.23%0.1M33.4M323.20K
2026-06-300.22%0.1M33.4M310.86K
2026-06-150.16%0.1M33.4M303.18K
2026-05-290.05%0.0M33.4M280.64K
2026-05-150.10%0.0M33.5M254.90K
2026-04-300.12%0.0M35.5M41.95K
2026-04-150.09%0.0M32.7M35.68K
2026-03-310.10%0.0M28.0M34.77K
2026-03-130.07%0.0M28.0M33.93K
2026-02-270.12%0.0M25.3M39.39K
2026-02-130.15%0.0M25.3M57.90K
2026-01-300.11%0.0M26.3M96.64K
2026-01-150.11%0.0M26.3M102.04K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.055.3743110.000.189-0.0090.000
call5.000.004.900.007.4540.000.000.159-0.0130.000
call7.500.004.900.008.4550.000.000.148-0.0140.000
put2.500.104.901.600.00011.000.00-0.813-0.0100.000
put5.002.106.500.000.0000.000.00-0.841-0.0120.000
put7.504.309.000.000.0000.000.00-0.852-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-23SEC
2026-07-238-KCurrent report2026-07-17SEC
2026-07-028-KCurrent report2026-06-26SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-228-KCurrent report2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2025-01-27SEC
2026-05-154Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-134/A2026-05-08SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-08SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-05-018-KCurrent report2026-05-01SEC
2026-04-24SCHEDULE 13DSEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-20ARSAnnual report to security holders. 2025-12-31SEC
2026-04-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05365.92K1123.01K1
2026-040000
2026-030000
2026-02007.88K2
2026-010096.12K9
2025-1237.36K300
2025-1121.76K100

Institutional holders

Manager% owned
Nantahala Capital Management, LLC14.42%
Rosalind Advisors, Inc.8.34%
Aberdeen Group plc7.96%
ORBIMED ADVISORS LLC6.69%
Parkman Healthcare Partners LLC5.16%
MARSHALL WACE, LLP3.97%
Soleus Capital Management, L.P.2.23%
PURA VIDA INVESTMENTS, LLC0.96%
INGALLS & SNYDER LLC0.79%
Affiance Financial, LLC0.54%

Funds

Fund% owned
abrdn Healthcare Investors3.72%
abrdn Healthcare Opportunities Fund2.69%
abrdn World Healthcare Fund1.48%
iShares Micro-Cap ETF0.25%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.02%

OakChart. NSPR. Cached 15 minutes.